Paricalcitol
As of the edition of 20 October 2026, Paricalcitol is a small molecule: marketed, first approved in 1998 (US); acts on VDR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Zemplar
- First approved
- 17 April 1998 (US)
- Approvals on record
- 19 in 4 regions
- Holder of the most recent approval
- Accord Healthcare; 4 holders in all
- Registered trials
- 76, 17 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Hormones; Cancer; Nutrition and metabolism; Digestive system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Paricalcitol.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VDR | Vitamin D3 receptor | P11473 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 5 | 1 | 3 |
| Phase 1 | 13 | 6 | 2 | 5 |
| Phase 2 | 16 | 15 | 0 | 1 |
| Phase 3 | 17 | 13 | 0 | 3 |
| Phase 4 | 21 | 14 | 0 | 5 |
| All trials | 76 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Abbott | Originator, Later holder and Lead sponsor of trials | 1998 to now |
| AbbVie | Acquired holder and Lead sponsor of trials | 2008 to now |
| Pfizer | Later holder | 2014 to now |
| Hikma Pharmaceuticals | Later holder | 2014 to now |
| Accord Healthcare | Later holder | 2016 to now |